好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

MRI Characteristics of Phase Rim Lesions in Chronic and Recent Acute MS Lesions
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
146

To determine the prevelance of phase rim lesions (PRLs), their association with acute new T2-lesions, and to quantify normalized T1-weighted intensity (nT1), normalized magnetization transfer ratio (nMTR) and diffusion tensor imaging radial diffusivity (DTI-RD) in T2-lesions with (PRL+) and without (PRL-) phase rims, in a relapsing multiple sclerosis (RMS) population.

Chronic active lesions are a subset of MS lesions thought to be represented by phase rim signals in susceptibility-weighted MR images.

PRL data was collected at follow-up weeks 72 and 96 in a subset of RMS patients from the AFFINITY trial [] (N=44) using standardized 3-Tesla, 3D isotropic multi-echo, gradient echo MRI.

27 of 44 (61.4%) patients had at least 1 PRL at week 72 follow-up, and 11 of 44 (25.0%) had at least 4 PRLs. Approximately 10% of PRLs identified at week 72 derived from acute new lesions formed between baseline and week 72.

Acute new T2 lesions that were PRL+ were larger at first detection (median size of 392 vs 52 mm3) and had lower nMTR on average at detection and recovery stages compared to those acute new T2 lesions that were rimless.

Chronic PRLs detected within T2 lesions pre-existing at baseline showed lower nMTR and higher RD at baseline. These lesions also showed a trend of decrease in nMTR and increase in RD from baseline to week 72 compared with chronic lesions without phase rims.

These data suggest that chronic T2 lesions with phase rims have more severe tissue injury than rimless chronic lesions. The minority of new T2 lesions that developed persistent phase rims were larger in size and also associated with more severe acute tissue damage as measured by nMTR decrease.

 

Support: This study is funded by Biogen

Authors/Disclosures
Colm Elliott (NeuroRx Research)
PRESENTER
Colm Elliott has received personal compensation for serving as an employee of NeuroRx Research.
Shibeshih Belachew, MD Dr. Belachew has received personal compensation for serving as an employee of Biogen Inc. Dr. Belachew has received stock or an ownership interest from Biogen Inc.
Elizabeth Fisher Elizabeth Fisher has received personal compensation for serving as an employee of Biogen. Elizabeth Fisher has stock in Biogen. Elizabeth Fisher has received intellectual property interests from a discovery or technology relating to health care.
Bing Zhu Bing Zhu has received personal compensation for serving as an employee of Biogen. Bing Zhu has received stock or an ownership interest from Biogen.
Dawei Liu Dawei Liu has received personal compensation for serving as an employee of Biogen. Dawei Liu has received stock or an ownership interest from Biogen.
Li Zhu Li Zhu has received personal compensation for serving as an employee of Biogen.
No disclosure on file
No disclosure on file
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ) Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clario.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Daniel P. Bradley Daniel Bradley has nothing to disclose.